CD163 and neoplasm: Precisely, metformin produced a decrease in tumor-promoting CD163+ macrophages and an increase in tumor-suppressive CD11c+ macrophages, in CD8+ cytotoxic T lymphocytes and CD20+ B lymphocytes.